Pulmonx Corporation (LUNG)Healthcare | Medical Devices | Redwood City, United States | NasdaqGS
1.46 USD
-0.08
(-5.195%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:23 a.m. EDT
The investment case for Pulmonx is currently broken by a catastrophic multi-year decline and deteriorating fundamentals. The stock has lost nearly 93% of its value over the last four years, with every single year showing negative returns, signaling a deep structural failure in the business model or market fit. Fundamentals confirm this distress: the company is burning cash with negative operating margins, shrinking revenue, and negative returns on equity and assets. While the balance sheet shows a high current ratio, this liquidity is likely propping up operations rather than indicating strength, especially given the negative free cash flow. The lack of a dividend reflects the company's inability to generate distributable earnings. On the short end, the overwhelming options activity in puts confirms that market participants are betting against the stock, expecting further declines. With no signs of a turnaround in revenue or profitability, and a price history that defines a complete collapse rather than a temporary setback, this is a security to avoid. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.082516 |
| AutoTheta | 0.084919 |
| MSTL | 0.088806 |
| AutoARIMA | 0.103187 |
| MSTL_105 | 0.118552 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.094 |
| Excess Kurtosis | -1.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 123.015 |
| Revenue per Share | 2.151 |
| Market Cap | 61,666,320 |
| Forward P/E | -1.40 |
| Beta | 0.31 |
| Profit Margins | -60.09% |
| Website | https://pulmonx.com |
As of July 11, 2026, 4:23 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (over 7,000 contracts at the $1 strike) compared to negligible call activity. This heavy put skew suggests a consensus expectation of further price weakness rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.42537314 |
| Address1 | 700 Chesapeake Drive |
| All Time High | 69.478 |
| All Time Low | 1.13 |
| Ask | 1.86 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 688,250 |
| Average Daily Volume3 Month | 493,139 |
| Average Volume | 493,139 |
| Average Volume10Days | 688,250 |
| Beta | 0.306 |
| Bid | 1.14 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.083 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,672,444,800 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.46 |
| Current Ratio | 4.906 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.605 |
| Day Low | 1.44 |
| Debt To Equity | 123.015 |
| Display Name | Pulmonx |
| Earnings Call Timestamp End | 1,777,494,600 |
| Earnings Call Timestamp Start | 1,777,494,600 |
| Earnings Timestamp | 1,777,492,800 |
| Earnings Timestamp End | 1,785,355,200 |
| Earnings Timestamp Start | 1,785,355,200 |
| Ebitda | -51,160,000 |
| Ebitda Margins | -0.57779 |
| Enterprise To Ebitda | -1.102 |
| Enterprise To Revenue | 0.637 |
| Enterprise Value | 56,387,316 |
| Eps Current Year | -1.142 |
| Eps Forward | -1.044 |
| Eps Trailing Twelve Months | -1.23 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.4014 |
| Fifty Day Average Change | 0.058600068 |
| Fifty Day Average Change Percent | 0.041815378 |
| Fifty Two Week Change Percent | -42.537315 |
| Fifty Two Week High | 3.88 |
| Fifty Two Week High Change | -2.42 |
| Fifty Two Week High Change Percent | -0.62371135 |
| Fifty Two Week Low | 1.13 |
| Fifty Two Week Low Change | 0.33000004 |
| Fifty Two Week Low Change Percent | 0.29203543 |
| Fifty Two Week Range | 1.13 - 3.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,559,000,000 |
| Float Shares | 36,970,646 |
| Forward Eps | -1.044 |
| Forward P E | -1.3984674 |
| Free Cashflow | -8,362,750 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 296 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.75488 |
| Gross Profits | 66,841,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.048850004 |
| Held Percent Institutions | 0.78827006 |
| Implied Shares Outstanding | 42,237,203 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,020-10-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. |
| Long Name | Pulmonx Corporation |
| Market | us_market |
| Market Cap | 61,666,320 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_8446085 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -53,209,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 61,666,316 |
| Number Of Analyst Opinions | 5 |
| Open | 1.46 |
| Operating Cashflow | -29,251,000 |
| Operating Margins | -0.62936 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 650 364 0400 |
| Previous Close | 1.54 |
| Price Eps Current Year | -1.278459 |
| Price Hint | 4 |
| Price To Book | 1.3481072 |
| Price To Sales Trailing12 Months | 0.69644046 |
| Profit Margins | -0.60093 |
| Quick Ratio | 3.853 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0799999 |
| Regular Market Change Percent | -5.1948 |
| Regular Market Day High | 1.605 |
| Regular Market Day Low | 1.44 |
| Regular Market Day Range | 1.44 - 1.605 |
| Regular Market Open | 1.46 |
| Regular Market Previous Close | 1.54 |
| Regular Market Price | 1.46 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 269,816 |
| Return On Assets | -0.24038 |
| Return On Equity | -0.86219 |
| Revenue Growth | -0.087 |
| Revenue Per Share | 2.151 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 42,237,203 |
| Shares Percent Shares Out | 0.0272 |
| Shares Short | 1,148,892 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,817,660 |
| Short Name | Pulmonx Corporation |
| Short Percent Of Float | 0.0323 |
| Short Ratio | 1.97 |
| Source Interval | 15 |
| State | CA |
| Symbol | LUNG |
| Target High Price | 5.0 |
| Target Low Price | 2.5 |
| Target Mean Price | 3.4 |
| Target Median Price | 3.0 |
| Total Cash | 61,572,000 |
| Total Cash Per Share | 1.458 |
| Total Debt | 56,293,000 |
| Total Revenue | 88,545,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.6357 |
| Two Hundred Day Average Change | -0.17569995 |
| Two Hundred Day Average Change Percent | -0.10741576 |
| Type Disp | Equity |
| Volume | 269,816 |
| Website | https://pulmonx.com |
| Zip | 94,063 |